Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481609 · ClinicalTrials.gov registry record · Early Phase 1
NAC Trial for Anosmia
A Early Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
NCT02481609 is a Early Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 29 participants.
The verdict
NCT02481609, a Early Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.
Interventions
- DRUG N-acetyl cysteine (NAC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02481609
The ClinicalTrials.gov registry entry for NCT02481609 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetyl cysteine (NAC) is the first listed.
NCT02481609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02481609 about?
NCT02481609 is a clinical study titled "NAC Trial for Anosmia". The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evide...
What is the current status of trial NCT02481609?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2014-07. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT02481609?
The interventions under investigation include: N-acetyl cysteine (NAC) (DRUG).
Who is sponsoring clinical trial NCT02481609?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.